Trial reportClinical and experimental immunology2020
Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.
Trial report in Clinical and experimental immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Changes in Serum IL-2 Levels Following a Single Oral Dose of Gluten
Assessing Immune Responses to Gluten: A Comparative Study of Liquid Versus Solid Gluten Administration
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Gastrointestinal and Extraintestinal Symptoms Among Subjects With Celiac Disease Undergoing a Dose-Specified Gluten Challenge: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2026Pooled it
- Therapeutic TG2 inhibition reverses systemic multiomic dysregulation in celiac disease.BMC medicine · 2026Trial
- Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.Gastroenterology · 2021Trial
- A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.Frontiers in immunology · 2021Trial
- Review Article: Accelerating Coeliac Disease Clinical Trials-Beyond Celiac Meeting With Industry, Academics, Patients and the FDA.Alimentary pharmacology & therapeutics · 2026Review
- Magnesium Status in Celiac Disease: Potential Links with Neuroinflammatory Pathways and Gut-Brain Axis Dysfunction.International journal of molecular sciences · 2026Review
- Targeted enzymatic therapy for coeliac disease.EMBO molecular medicine · 2026Article
- Advanced human organoid-on-chip with physiological cellular complexity reveals bidirectional secretion patterns.iScience · 2026Article
- A set of serum proteomic biomarkers differentiates celiac children from age and human leukocyte antigen-matched healthy controls.Journal of pediatric gastroenterology and nutrition · 2026Article
- Plasma Proteins Invariant to Diet in Celiac Disease: Results From a Proteomics Study on the UK Biobank.Gastro hep advances · 2026Article
- Mechanisms of inflammation in premature ovarian insufficiency and advances in therapeutic studies.Frontiers in immunology · 2026Review
- Challenges in the Pediatric Celiac Disease Diagnosis: An Up-to-Date Review.Diagnostics (Basel, Switzerland) · 2025Review
- Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation.Alimentary pharmacology & therapeutics · 2025Review
- Diagnosis of celiac disease on a gluten-free diet: a multicenter prospective quasi-experimental clinical study.BMC medicine · 2025Article
- Celiac Disease and Gluten Cross-Contact: How Much is too Much?Current nutrition reports · 2025Review
- Acute gluten-induced inflammatory response highlights CCL20 as a potential biomarker for celiac disease.Frontiers in immunology · 2025Article
- InTiCAR: Network-based identification of significant inter-tissue communicators for autoimmune diseases.Computational and structural biotechnology journal · 2025Article
- IL-22, a vital cytokine in autoimmune diseases.Clinical and experimental immunology · 2024Review
- Article
- The Role of Viruses in the Pathogenesis of Immune-Mediated Gastro-Intestinal Diseases.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokines have been extensively studied in coeliac disease, but cytokine release related to exposure to gluten and associated symptoms has only recently been described. Prominent, early elevations in serum interleukin (IL)-2 after gluten support a central role for T cell activation in the clinical reactions to gluten in coeliac disease. The aim of this study was to establish a quantitative hierarchy of serum cytokines and their relation to symptoms in patients with coeliac disease during gluten-mediated cytokine release reactions. Sera were analyzed from coeliac disease patients on a gluten free-diet (n = 25) and from a parallel cohort of healthy volunteers (n = 25) who underwent an unmasked gluten challenge. Sera were collected at baseline and 2, 4 and 6 h after consuming 10 g vital wheat gluten flour; 187 cytokines were assessed. Confirmatory analyses were performed by high-sensitivity electrochemiluminescence immunoassay. Cytokine elevations were correlated with symptoms. Cytokine release following gluten challenge in coeliac disease patients included significant elevations of IL-2, chemokine (C-C motif) ligand 20 (CCL20), IL-6, chemokine (C-X-C motif) ligand (CXCL)9, CXCL8, interferon (IFN)-γ, IL-10, IL-22, IL-17A, tumour necrosis factor (TNF)-α, CCL2 and amphiregulin. IL-2 and IL-17A were earliest to rise. Peak levels of cytokines were generally at 4 h. IL-2 increased most (median 57-fold), then CCL20 (median 10-fold). Cytokine changes were strongly correlated with one another, and the most severely symptomatic patients had the highest elevations. Early elevations of IL-2, IL-17A, IL-22 and IFN-γ after gluten in patients with coeliac disease implicates rapidly activated T cells as their probable source. Cytokine release after gluten could aid in monitoring experimental treatments and support diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.